Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to the Usual Radiation Treatment for Newly Diagnosed Early Stage High Intermediate Risk Endometrial Cancer

NCT04214067 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

164

Enrollment

NIH

Sponsor class

Conditions

Endometrial Endometrioid Adenocarcinoma
Stage I Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8
Stage II Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8

Interventions

PROCEDURE: Biospecimen Collection
RADIATION: Brachytherapy
PROCEDURE: Computed Tomography
RADIATION: External Beam Radiation Therapy
PROCEDURE: Magnetic Resonance Imaging
BIOLOGICAL: Pembrolizumab
OTHER: Quality-of-Life Assessment
OTHER: Questionnaire Administration
PROCEDURE: X-Ray Imaging

Sponsor

National Cancer Institute (NCI)

Collaborators

[object Object]